(Q38167294)

30 August 2017

title

Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies (English)

1 reference

30 August 2017

1 reference

1 reference

Katelijne van de Vooren

series ordinal

1

object named as

Katelijne van de Vooren

1 reference

30 August 2017

Silvy Duranti

2

1 reference

30 August 2017

Alessandro Curto

series ordinal

3

1 reference

30 August 2017

Livio Garattini

series ordinal

4

1 reference

30 August 2017

publication date

1 January 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

32

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

29-45

1 reference

Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006).

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Impact of the pneumococcal conjugate vaccine on otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

The diffusion of health economics knowledge in Europe : The EURONHEED (European Network of Health Economics Evaluation Database) project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Modeling in pharmacoeconomic studies: funding sources and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Data from electronic patient records are suitable for surveillance of antibiotic prescriptions for respiratory tract infections in primary health care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Cost-utility of the cochlear implant in adults: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Morbidity and mortality of pneumococcal meningitis and serotypes of causative strains prior to introduction of the 7-valent conjugant pneumococcal vaccine in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Serotype incidence and antibiotic susceptibility of Streptococcus pneumoniae causing invasive disease in Scotland, 1999-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

[Prevalence of somatic diseases in German children and adolescents. Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Burden of otitis media and pneumonia in children up to 6 years of age: results of the LISA birth cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Approaches to estimate the population-based incidence of community acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Pneumococcal meningitis in the intensive care unit: prognostic factors of clinical outcome in a series of 80 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Pneumococcal meningitis in adults: Spectrum of complications and prognostic factors in a series of 87 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Trends in doctor consultations, antibiotic prescription, and specialist referrals for otitis media in children: 1995-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae-associated disease following vaccination with PCV-7: a multicountry analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged ≥65 years in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0113-Y

Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland

21 January 2018

1 reference

12 December 2020

[Epidemiology and burden of acute otitis media in Valencia (Spain)]

1 reference

12 December 2020

Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries

1 reference

12 December 2020

Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.

1 reference

12 December 2020

Invasive pneumococcal infections in Canadian children, 1991-1998: implications for new vaccination strategies. Canadian Paediatric Society/Laboratory Centre for Disease Control Immunization Monitoring Program, Active (IMPACT).

1 reference

12 December 2020

Surveillance of invasive Streptococcus pneumoniae infection in Quebec, Canada, from 1984 to 1986: serotype distribution, antimicrobial susceptibility, and clinical characteristics.

1 reference

12 December 2020

Pricing human papillomavirus vaccines: lessons from Italy

1 reference

12 December 2020

Epidemiology of acute suppurative otitis media

1 reference

12 December 2020

The epidemiology of pneumococcal infections--the Swedish experience

1 reference

12 December 2020

Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006.

1 reference

12 December 2020

Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps

1 reference

12 December 2020

Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model

1 reference

12 December 2020

Consultations for middle ear disease, antibiotic prescribing and risk factors for reattendance: a case-linked cohort study.

1 reference

12 December 2020

Clinical features and prognostic factors in adults with bacterial meningitis

1 reference

12 December 2020

Estimating the cost-effectiveness of pneumococcal conjugate vaccination in Brazil

1 reference

12 December 2020

Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland

1 reference

12 December 2020

Parents' utilities for outcomes of occult bacteremia.

1 reference

12 December 2020

Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults

1 reference

12 December 2020

[Epidemiology of community-acquired pneumonia in children aged less than 5 years old in the Autonomous Community of Valencia (Spain)]

1 reference

12 December 2020

A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children

1 reference

12 December 2020

Invasive pneumococcal infections in Southwestern Sweden: a second follow-up period of 15 years

1 reference

12 December 2020

Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study

1 reference

12 December 2020

Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003

1 reference

12 December 2020

The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine

1 reference

12 December 2020

Vaccines for preventing pneumococcal infection in adults

1 reference

12 December 2020

Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects

1 reference

12 December 2020

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands

1 reference

12 December 2020

10.1007/S40273-013-0113-Y

Identifiers

DOI

1 reference

30 August 2017

1 reference